Kestra teams up with Biobeat in an exclusive deal, investing $5M to add continuous blood pressure monitoring to the ASSURE ...

WASHINGTON, DC — Some patients deemed high risk for sudden cardiac death in the first weeks following an acute MI, when guidelines are strict about avoiding use of implantable ...

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that the LifeVest® ...

Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today ...

Kestra Medical Technologies (Nasdaq:KMTS) announced today that it entered into a strategic collaboration with Biobeat ...

BARCELONA, SPAIN — Data recorded by a wearable cardiac defibrillator (WCD) can help physicians assess whether a patient at high risk of sudden cardiac death should receive an implantable cardioverter ...

CHELMSFORD, Mass.--(BUSINESS WIRE)--The American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS) have issued guidelines for the wearable cardioverter ...

KIRKLAND, Wash.--(BUSINESS WIRE)--Kestra Medical Technologies announced today that the ASSURE ® Wearable Cardioverter Defibrillator (WCD) system is now available in-network to over 100 million ...

Asahi Kasei announced that ZOLL® Medical has launched the next-generation LifeVest® wearable cardioverter defibrillator (WCD) ...

Asahi Kasei announced that ZOLL® Medical, an Asahi Kasei company, has launched the next-generation LifeVest® wearable ...

Please provide your email address to receive an email when new articles are posted on . A novel adhesive-based wearable cardioverter defibrillator exceeded its safety and efficacy performance goals.